Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Abstract

Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.

Keywords

ErlotinibMedicineLung cancerHazard ratioInternal medicineErlotinib HydrochlorideChemotherapyRandomizationPlaceboPerformance statusOncologySurgeryEpidermal growth factor receptorGastroenterologyCancerRandomized controlled trialConfidence intervalPathology

Affiliated Institutions

Related Publications

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

Pui San Tan , Gilberto Lopes , Sanchalika Acharyya +2 more

Maintenance treatments show clinically meaningful survival benefits in good performance status patients with advanced NSCLC not progressing after first-line chemotherapy. Benefi...

2015 European Journal of Cancer 17 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

Trastuzumab-Induced Hepatotoxicity: A Case Report

D. Vucicevic , Elizabeth J. Carey , Nina J. Karlin

<b><i>Background: </i></b>Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overe...

2013 Breast Care 4416 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Publication Info

Year: 2005
Type: article
Volume: 353
Issue: 2
Pages: 123-132
Citations: 5425
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

5425

OpenAlex

Cite This

APA Style

                            
                                
                                    Frances A. Shepherd, 
                                
                                    José Rodrigues Pereira, 
                                
                                    Tudor‐Eliade Ciuleanu
                                
                                et al.
                            
                            (2005). 
                            Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. 
                            New England Journal of Medicine
                            , 353
                            (2)
                            , 123-132.
                            https://doi.org/10.1056/nejmoa050753
                        

Identifiers

DOI: 10.1056/nejmoa050753